- Conditions
- Ulcerative Colitis Acute
- Interventions
- Oral Upadacitinib, Intravenous Methylprednisolone, Oral Upadacitinib Placebo, Oral prednisolone Taper, Oral Prednisone - Hospital Dose Steroids
- Drug
- Lead sponsor
- Berinstein, Jeffrey
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 2,658
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Carboplatin, Computed Tomography, Paclitaxel, Pembrolizumab, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 813 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 370
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 272 more
- Conditions
- Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell
- Interventions
- Pegylated Interferon alpha-2b, Capecitabine, 5-FU
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Trauma, Hemorrhagic Shock
- Interventions
- Type AB plasma, Crystalloid fluid (standard of care for resuscitation)
- Biological · Drug
- Lead sponsor
- Denver Health and Hospital Authority
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Hypotension
- Interventions
- Phenylephrine
- Drug
- Lead sponsor
- West-Ward Pharmaceutical
- Industry
- Eligibility
- 12 Years to 16 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2024
- U.S. locations
- 10
- States / cities
- Wilmington, Delaware • Washington D.C., District of Columbia • Miami, Florida + 7 more
- Conditions
- Colorectal Cancer, Metastatic Cancer
- Interventions
- dexamethasone, floxuridine, fluorouracil, leucovorin calcium, laparotomy, conventional surgery
- Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 11
- States / cities
- Cedar Rapids, Iowa • Des Moines, Iowa • Papillion, Nebraska + 5 more
- Conditions
- Solid Tumor, Adult, Mesothelioma, NSCLC
- Interventions
- VT3989, Nivolumab & Ipilimumab, Osimertinib, Pemetrexed/Carboplatin
- Drug
- Lead sponsor
- Vivace Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 434 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 9
- States / cities
- San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 5 more
- Conditions
- Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Sickle Cell Hemoglobin C Disease, Pain Crisis
- Interventions
- Buprenorphine Buccal Film [Belbuca]
- Drug
- Lead sponsor
- Natasha Archer
- Other
- Eligibility
- 12 Years to 22 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV-1-infection
- Interventions
- Albuvirtide, 3BNC117, Baseline ART
- Drug
- Lead sponsor
- Frontier Biotechnologies Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 7
- States / cities
- Palm Springs, California • San Francisco, California • Ft. Pierce, Florida + 4 more
- Conditions
- Intracerebral Hemorrhage, ICH - Intracerebral Hemorrhage
- Interventions
- Minimally Invasive surgery (MIS), Deferoxamine, Standard Medical Care (SMD)
- Procedure · Drug · Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder, Metabolism Disorder, Aplastic Anemia, Myelodysplastic Syndromes, Chronic Leukemia, Lymphoma, Multiple Myeloma, Solid Tumor
- Interventions
- Total Body Irradiation 1200 cGy, Total Body Irradiation 200 cGy, Cyclophosphamide, Mesna, Cord Blood Infusion, Busulfan, Fludarabine, Melphalan
- Radiation · Drug · Procedure
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 2 Months to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Acute Kidney Injury
- Interventions
- Conservative dialysis strategy, TIW dialysis strategy
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- Ezabenlimab, BI 754111
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 6
- States / cities
- Miami, Florida • Sarasota, Florida • Hackensack, New Jersey + 3 more
- Conditions
- Status Epilepticus
- Interventions
- propofol, thiopental/pentobarbital
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Suicide, Attempted
- Interventions
- Ketamine Hydrochloride, Saline, CAMS Therapy
- Drug · Behavioral
- Lead sponsor
- Tatiana Falcone, MD
- Other
- Eligibility
- 14 Years to 30 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Pharmacokinetics of ASP3662, Displacement of Radiotracer, Healthy Volunteers
- Interventions
- [11C]AS2471907, Positron Emission Tomography (PET), ASP3662
- Other · Radiation · Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Crohn Disease
- Interventions
- CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Prednisone/Methylprenisolone, Palifermin, ATG, Clofarabine, Melphalan, Total Body Irradiation, Rituximab
- Device · Drug · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2040
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Azacitidine, Decitabine, Venetoclax
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Myelodysplastic Syndromes
- Interventions
- filgrastim, clofarabine, cytarabine, microarray analysis, biopsy
- Biological · Drug · Genetic + 1 more
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 120 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Pain
- Interventions
- Magnesium, Normal saline
- Drug
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 4 Years to 10 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
- Interventions
- filgrastim, carboplatin, etoposide, ifosfamide, paclitaxel, autologous bone marrow transplantation, bone marrow ablation with stem cell support
- Biological · Drug · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 16 Years to 120 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2014
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Glioblastoma
- Interventions
- Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
- Drug · Radiation · Biological
- Lead sponsor
- Global Coalition for Adaptive Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
- Conditions
- End Stage Liver DIsease, Obesity, Acute Kidney Injury
- Interventions
- Direct Peritoneal Resuscitation
- Procedure
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Multiple Myeloma
- Interventions
- Cisplatin, Cyclophosphamide, Adriamycin, Etoposide, Melphalan, Thalidomide, Dexamethasone
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas